Corrigendum: Defining a radiomic response phenotype: A pilot study using targeted therapy in NSCLC (Scientific Reports (2016) 6 (33860) DOI: 10.1038/srep33860);Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Aerts, Hugo J W L ^a,b   Grossmann, Patrick ^a,b   Tan, Yongqiang ^c   Oxnard, Geoffrey G ^d   Rizvi, Naiyer ^c   Schwartz, Lawrence H ^c   Zhao, Binsheng ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Farber Cancer Institute ^*  (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; QUINAZOLINE DERIVATIVE;

CLINICAL TRIAL; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; GENETICS; HUMAN; LUNG TUMOR; MALE; MUTATION; NEOADJUVANT THERAPY; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL; PILOT STUDY; X-RAY COMPUTED TOMOGRAPHY;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOADJUVANT THERAPY; PILOT PROJECTS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84988511917     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep41197     Document Type: Erratum

References (32)

1. Therasse, P. et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J. Natl. Cancer Inst. 92, 205-216 (2000).
2. Organization, W. H., Others. WHO handbook for reporting results of cancer treatment (1979).
3. Zhao, B. et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin. Cancer Res. 16, 4647-4653 (2010).
4. Aerts, H. J. W. L. et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat. Commun. 5, 4006 (2014).
5. Kumar, V. et al. Radiomics: the process and the challenges. Magn. Reson. Imaging 30, 1234-1248 (2012).
6. Lambin, P. et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur. J. Cancer 48, 441-446 (2012).
7. Huang, Y. et al. Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology 152234 (2016).
8. Coroller, T. P. et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother. Oncol. 114, 345-350 (2015).
9. Yang, Y. et al. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. Lung Cancer 87, 272-277 (2015).
10. Lee, H.-J. et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 268, 254-264 (2013).
11. Gevaert, O. et al. Non-Small Cell Lung Cancer: Identifying Prognostic Imaging Biomarkers by Leveraging Public Gene Expression Microarray Data-Methods and Preliminary Results. Radiology 264, 387-396 (2012).
12. Rizvi, N. A. et al. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin. Cancer Res. 17, 3500-3506 (2011).
13. Pan, Q., Pao, W., Ladanyi, M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J. Mol. Diagn. 7, 396-403 (2005).
14. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306-13311 (2004).
15. Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005).
16. Zhao, B., Reeves, A. P., Yankelevitz, D. F., Henschke, C. I. Three-dimensional multicriterion automatic segmentation of pulmonary nodules of helical computed tomography images. Opt. Eng. 38, 1340-1347 (1999).
17. Fawcett, T. An introduction to ROC analysis. Pattern Recognit. Lett. 27, 861-874 (2006).
18. Team, R. C. R: A language and environment for statistical computing (2012).
19. RIDER Collections-The Cancer Imaging Archive (TCIA) Public Access-Cancer Imaging Archive Wiki. Available at: https://wiki. cancerimagingarchive.net/display/Public/RIDER+ Collections. (Accessed: 10th September 2015).
20. Zhao, B. et al. Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non-Small Cell Lung Cancer. Radiology 252, 263-272 (2009).
21. Pirker, R. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525-1531 (2009).
22. Lynch, T. J. et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J. Clin. Oncol. 28, 911-917 (2010).
23. Khambata-Ford, S. et al. Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 28, 918-927 (2010).
24. Hirsch, F. R. et al. Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non-Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. J. Clin. Oncol. 26, 3351-3357 (2008).
25. Grove, O. et al. Quantitative Computed Tomographic Descriptors Associate Tumor Shape Complexity and Intratumor Heterogeneity with Prognosis in Lung Adenocarcinoma. PLoS One 10, e0118261 (2015).
26. Hawkins, S. H. et al. Predicting Outcomes of Nonsmall Cell Lung Cancer Using CT Image Features. IEEE Access 2, 1418-1426 (2014).
27. Balagurunathan, Y. et al. Reproducibility and Prognosis of Quantitative Features Extracted from CT Images. Transl. Oncol. 7, 72-87 (2014).
28. Parmar, C. et al. Robust Radiomics feature quantification using semiautomatic volumetric segmentation. PLoS One 9, e102107 (2014).
29. Parmar, C., Grossmann, P., Bussink, J., Lambin, P., Aerts, H. J. W. L. Machine Learning methods for Quantitative Radiomic Biomarkers. Sci. Rep. 5, 13087 (2015).
30. Clarke, L. P. et al. The Quantitative Imaging Network: NCI's Historical Perspective and Planned Goals. Transl. Oncol. 7, 1-4 (2014).
31. Buckler, A. J. et al. Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology 259, 875-884 (2011).
32. Buckler, A. J., Bresolin, L., Dunnick, N. R., Sullivan, D. C., Group. A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging. Radiology 258, 906-914 (2011).